The specialist in small molecule drug development, has this week seen the admission of shares to trading on AIM relating to a placing of £850k at a price of 0.65p. The net proceeds of the placing will be used to progress the Company's TYK2/JAK1 drug development programmes as well as for working capital purposes. We leave our FYJun19E profit and loss projections unchanged, but have amended our cashflow forecast accordingly, leaving Sareum with an estimated year end cash balance of £
09 Nov 2018
£850k raised to progress proprietary TYK2/JAK1 programmes into preclinical development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
£850k raised to progress proprietary TYK2/JAK1 programmes into preclinical development
Sareum Holdings plc (SAR:LON) | 24.2 -0.6 (-9.3%) | Mkt Cap: 24.6m
- Published:
09 Nov 2018 -
Author:
Derren Nathan -
Pages:
6
The specialist in small molecule drug development, has this week seen the admission of shares to trading on AIM relating to a placing of £850k at a price of 0.65p. The net proceeds of the placing will be used to progress the Company's TYK2/JAK1 drug development programmes as well as for working capital purposes. We leave our FYJun19E profit and loss projections unchanged, but have amended our cashflow forecast accordingly, leaving Sareum with an estimated year end cash balance of £